SMTI

Sanara Medtech Inc

SMTI, USA

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

https://sanaramedtech.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
SMTI
stock
SMTI

Technical Reactions to SMTI Trends in Macro Strategies news.stocktradersdaily.com

Read more →
SMTI
stock
SMTI

Sanara MedTech Inc. Announces U.S. Market Launch Timeline for OsSticâ„¢ Synthetic Injectable Bio-Adhesive in Q1 2027 Following Key Milestones Quiver Quantitative

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$41

Analyst Picks

Strong Buy

1

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

37.73

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-495.25 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-42.78 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

4.24 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

10.58

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 16.26% of the total shares of Sanara Medtech Inc

1.

BlackRock Inc

(2.7352%)

since

2025/06/30

2.

Vanguard Group Inc

(1.9768%)

since

2025/06/30

3.

Stonebridge Wealth Management, LLC

(1.3442%)

since

2025/06/30

4.

Vanguard Total Stock Mkt Idx Inv

(1.0962%)

since

2025/07/31

5.

iShares Russell 2000 ETF

(0.9652%)

since

2025/08/31

6.

Geode Capital Management, LLC

(0.8732%)

since

2025/06/30

7.

Marshall Wace Asset Management Ltd

(0.8033%)

since

2025/06/30

8.

State Street Corp

(0.7337%)

since

2025/06/30

9.

Renaissance Technologies Corp

(0.4201%)

since

2025/06/30

10.

Vanguard Institutional Extnd Mkt Idx Tr

(0.4046%)

since

2025/07/31

11.

Northern Trust Corp

(0.3837%)

since

2025/06/30

12.

Dimensional Fund Advisors, Inc.

(0.3704%)

since

2025/06/30

13.

Royal Bank of Canada

(0.3665%)

since

2025/06/30

14.

Fidelity Small Cap Index

(0.3357%)

since

2025/06/30

15.

iShares Russell 2000 Growth ETF

(0.3259%)

since

2025/08/31

16.

Janney Montgomery Scott LLC

(0.2812%)

since

2025/06/30

17.

Citadel Advisors Llc

(0.2558%)

since

2025/06/30

18.

Morgan Stanley - Brokerage Accounts

(0.2372%)

since

2025/06/30

19.

Fidelity Extended Market Index

(0.211%)

since

2025/07/31

20.

Vanguard Russell 2000 ETF

(0.1628%)

since

2025/07/31

21.

State St Russell Sm Cap® Indx SL Cl I

(0.1606%)

since

2025/08/31

22.

Bank of New York Mellon Corp

(0.1538%)

since

2025/06/30

23.

HSBC Holdings PLC

(0.1504%)

since

2025/06/30

24.

Stephens Inc

(0.1437%)

since

2025/06/30

25.

Salem Investment Counselors Inc

(0.126%)

since

2025/06/30

26.

Susquehanna International Group, LLP

(0.1039%)

since

2025/06/30

27.

Charles Schwab Investment Management Inc

(0.1036%)

since

2025/06/30

28.

Barclays PLC

(0.0994%)

since

2025/06/30

29.

DFA US Small Cap I

(0.0992%)

since

2025/07/31

30.

Extended Equity Market Fund K

(0.0966%)

since

2025/06/30

31.

Russell 2500â„¢ Index Fund F

(0.0922%)

since

2025/06/30

32.

Schwab Small Cap Index

(0.085%)

since

2025/07/31

33.

NT R2000 Index Fund - NL

(0.0821%)

since

2025/06/30

34.

iShares Micro-Cap ETF

(0.0774%)

since

2025/08/31

35.

Fidelity Total Market Index

(0.074%)

since

2025/07/31

36.

Dimensional US Small Cap ETF

(0.0725%)

since

2025/08/29

37.

SPDR® Russell 2000 US Small Cap ETF

(0.0681%)

since

2025/08/31

38.

NT R2000 Index Fund - DC - NL - 3

(0.0655%)

since

2025/06/30

39.

WisdomTree US SmallCap Earnings ETF

(0.0629%)

since

2025/08/29

40.

iShares Russell 2000 Small-Cap Idx Instl

(0.0583%)

since

2025/07/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2026-03-31

EPS Estimate

0.175

Latest Release

Date

2025-09-30

EPS Actual

-3.4

EPS Estimate

-0.255

EPS Difference

-3.145

Surprise Percent

-1233.3333%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(3.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(2.5)
Momentum
Moderate Momentum(5.5)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Moderate Quality(3.5)
Value
Overpriced(2)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.